HALO — Halozyme Therapeutics Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapSuper Stock

Annual income statement for Halozyme Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	268	443	660	829	1,015
Cost of Revenue
Gross Profit	224	362	521	637	856
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	123	188	395	492	464
Operating Profit	144	255	265	338	551
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	129	249	249	348	557
Provision for Income Taxes
Net Income After Taxes	129	403	202	282	444
Net Income Before Extraordinary Items
Net Income	129	403	202	282	444
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	129	403	202	282	444
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.912	2.84	1.58	2.11	3.43